Passage BIO, Inc. Files 8-K Report

Ticker: PASG · Form: 8-K · Filed: Jul 29, 2025 · CIK: 1787297

Sentiment: neutral

Topics: 8-k, other-event

TL;DR

Passage BIO filed an 8-K for an 'Other Event' on 7/28. Details TBD.

AI Summary

On July 28, 2025, Passage BIO, Inc. filed an 8-K report detailing an "Other Event." The filing does not disclose specific details about the event itself, but it was submitted on July 29, 2025, and pertains to the company's operations as of July 28, 2025. Passage BIO, Inc. is a biotechnology company incorporated in Delaware.

Why It Matters

This 8-K filing indicates a material event has occurred or is being disclosed by Passage BIO, Inc., requiring immediate reporting to the SEC and investors.

Risk Assessment

Risk Level: medium — The filing is an 8-K for 'Other Events,' which can range from routine disclosures to significant corporate actions, making the immediate risk level uncertain without further details.

Key Players & Entities

FAQ

What specific event is Passage BIO, Inc. reporting in this 8-K filing?

The filing is categorized under 'Other Events' and does not provide specific details about the event itself within the provided text.

When was the earliest event reported by Passage BIO, Inc. in this filing?

The earliest event reported was on July 28, 2025.

On what date was this 8-K report filed with the SEC?

The report was filed on July 29, 2025.

What is the principal executive office address for Passage BIO, Inc.?

The principal executive offices are located at One Commerce Square, 2005 Market Street, 39th Floor, Philadelphia, PA 19103.

What is the Commission File Number for Passage BIO, Inc.?

The Commission File Number for Passage BIO, Inc. is 001-39231.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 29, 2025 regarding Passage BIO, Inc. (PASG).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing